Kimia Biosciences
34.78
+1.50(+4.51%)
Market Cap₹164.60 Cr
PE Ratio17.42
IndustryHealthcare
Company Performance:
1D+4.51%
1M+12.78%
6M-12.94%
1Y-24.23%
5Y-15.38%
View Company Insightsright
More news about Kimia Biosciences
06Jan 26
Kimia Biosciences Appoints Naveen Sharma as CFO After Leadership Change
Kimia Biosciences Limited has successfully transitioned its financial leadership with the appointment of Mr. Naveen Sharma as Chief Financial Officer on January 7, 2026, immediately following the resignation of former CFO Pradip Kumar Sharma. The new CFO brings over 18 years of chartered accountancy experience across financial services, manufacturing, and banking sectors, with expertise in digital transformation and regulatory compliance.
 no imag found
31Dec 25
Kimia Biosciences Non-Executive Director Vipul Goel Resigns Effective December 31, 2025
Kimia Biosciences Limited announced that Non-Executive Director Mr. Vipul Goel (DIN: 00064274) has resigned from his position effective December 31, 2025, due to personal reasons. The company has accepted his resignation and completed all regulatory compliance requirements under SEBI regulations. The announcement was formally communicated to BSE Limited with all necessary documentation and disclosures.
 no imag found
29Dec 25
Kimia Biosciences Appoints Pharmaceutical Veteran as Additional Executive Director
Kimia Biosciences Limited has appointed Mr. Kaku Vijaya Shekhar Reddy as Additional Executive Director. Mr. Reddy brings over 40 years of experience in the pharmaceutical industry, particularly in API manufacturing. His appointment, made on December 29, 2025, is subject to shareholder approval. Mr. Reddy has expertise in operations management, project execution, regulatory compliance, and business strategy. He has held senior leadership positions including Managing Director and Chief Operating Officer in reputed pharmaceutical organizations.
 no imag found
15Nov 25
Kimia Biosciences Reports Rs 101.40 Lakh Net Profit in Q2
Kimia Biosciences, an Indian pharmaceutical company, released its Q2 and H1 FY2026 unaudited financial results. The company reported a total revenue of Rs 3,271.76 lakhs and a net profit of Rs 101.40 lakhs for Q2. For H1, net cash from operating activities was Rs 44.15 lakhs. The company faced increased borrowings and higher finance costs. The Board approved these results on November 14, 2025, in compliance with SEBI regulations.
 no imag found
12Nov 25
Kimia Biosciences Director Prasad Raju Steps Down Citing Medical Reasons
Mr. Prasad Raju (Ramakrishnavara Prasada Raju Mantena), a director of Kimia Biosciences Limited, has resigned effective November 12, 2025, citing medical advice and personal well-being. The company has accepted his resignation and relieved him from duties on the same date. Mr. Raju expressed gratitude to the Board and colleagues, assuring full support for a smooth transition. The company has not provided information on a successor but confirmed no material reasons for the resignation beyond those stated.
 no imag found
16Aug 25
Kimia Biosciences Reports Mixed Q1 FY2026 Results with Sequential Growth
Kimia Biosciences Limited released unaudited standalone financial results for Q1 FY2026 ended June 30, 2025. Total income was ₹6,103.00 lakhs (-1.61% YoY, +20.18% QoQ), net profit ₹613.00 lakhs (-1.13% YoY, +6.06% QoQ), and EPS ₹4.31 (-2.05% YoY, +6.42% QoQ). The company showed resilience with significant sequential growth despite slight year-over-year declines. Results were published in English and Hindi newspapers for regulatory compliance.
 no imag found
14Aug 25
Kimia Biosciences Approves Q1 Results, Appoints New CFO, and Raises ₹2 Crore Loan
Kimia Biosciences announced Q1 FY2024 results with revenue growth of 5.29% but a 57.97% decrease in profit. The company appointed Mr. Pradip Kumar Sharma as the new CFO and approved an unsecured loan of ₹2 crores at 8% interest. The Board also addressed a BSE warning letter regarding compliance with SEBI regulations on annual report submission.
 no imag found
Kimia Biosciences
34.78
+1.50
(+4.51%)
1 Year Returns:-24.23%
Industry Peers
Sun Pharmaceutical
1,724.40
(+0.64%)
Divis Laboratories
6,291.00
(-0.10%)
Torrent Pharmaceuticals
4,241.70
(+0.36%)
Cipla
1,341.10
(+0.92%)
Dr Reddys Laboratories
1,280.40
(-0.15%)
Lupin
2,219.40
(-0.42%)
Zydus Life Science
900.75
(-0.18%)
Mankind Pharma
2,024.30
(-0.75%)
Aurobindo Pharma
1,158.80
(-1.08%)
Alkem Laboratories
5,392.00
(+0.28%)